Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Q2 Revenues Fall 60 Percent

NEW YORK (GenomeWeb) – Biocept today reported a 60 percent drop in its second quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based company said that for the three months ended June 30, revenues fell to $19,245 from $48,369 in the year-ago quarter. The decline, it said, resulted primarily from lower sample volume related to a collaboration with the Dana-Farber Cancer Institute that is approaching completion.

Biocept's net loss for the quarter was $3 million, or $.67 per share, compared to a net loss of $2 million, or $10.83 per share in Q2 2013. In the recently completed quarter, the firm used approximately 4.4 million shares to calculate its loss on a per-share basis, compared to 182,304 shares in the year-ago period. Biocept went public in February with an offering of 1.9 million shares.

The company said it had $12.5 million in cash and cash equivalents as of the end of Q2. In May Biocept entered into a $10 million loan and security agreement with Oxford Finance.

In afternoon trading on Monday, shares of Biocept were down about 4 percent on the Nasdaq at $4.70.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.